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Abstract 
Background: The evidence indicates that vitamin D [25(OH)D] improves 
glycaemic outcomes in type 2 Diabetes mellitus patients. The outcome meas-
ures used to determine the accuracy of this hypothesis are: glycosylated he-
moglobin (HbA1c), fasting plasma glucose (FPG) and homeostasis model as-
sessment-insulin resistance (HOMA-IR). Methods: We performed a syste-
matic review and meta-analysis which included all previous randomised con-
trolled trial (RCT) studies that assessed the effects of vitamin D on glucose 
metabolism. We carried out an extensive electronic database search of pub-
lished and unpublished RCTs, evaluating the association between vitamin D 
and glycaemic outcomes in type 2 diabetes mellitus patients. We searched 
Cochrane Library, PubMed, EMBASE, CINAHL Plus with Full Text, 
MEDLINE, BioMed Central, Turning Research Into Practice (TRIP), Health 
Technology Assessment (HTA), and Latin American and Caribbean Health 
Sciences (LILIACS) between the years 2005 and 2016. The full texts of relevant 
studies were retrieved and a snowballing technique was used to discover fur-
ther studies missed from the initial database search. This was done by 
hand-searching for references within the retrieved articles. Results: A total of 
17 studies were included in the review. The pooled effect of 15 studies that 
measured HbA1c showed an insignificant effect of vitamin D on HbA1c 
(Mean difference (MD) = −0.06 mmol/l; 95% CI = −0.26 to 0.14; I2 = 76%). A 
pooled analysis of seven studies that measured the effect of vitamin D on 
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blood glucose also found no significant effect of vitamin D on T2DM (MD = 
−0.03 mmol/l; 95% CI = −0.69 to 0.63; I2 = 76%). Three studies that analysed 
the effect of vitamin D on insulin sensitivity also observed no significant effect 
(MD = −1.51 mmol/l; 95% CI = −3.61 to 0.60; I2 = 67%). Conclusion: In con-
clusion, although vitamin D has been extensively studied in relation to some 
glycaemic outcomes and some indications that increased plasma vitamin D 
concentrations might be linked to prevention of T2DM, firm universal con-
clusions about its benefits cannot be drawn. Further studies with better de-
signed trials and larger sample sizes are needed to draw firmer conclusions. 
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1. Introduction 
Globally, type 2 diabetes mellitus (T2DM) is shifting in two directions: first, 
from being predominantly a disease of the affluent toward disadvantaged popu-
lations and nations; and second, from being a disease of old age toward expo-
nential growth among young people [1] [2] [3]. Some of the factors associated 
with these shifting patterns include uneven distribution of health determinants 
and the unintended consequences of phenomena such as aging populations, 
growing industrialization, urbanization, and market globalization [4] [5] [6] [7] 
[8]. While the high-income countries have benefited from these phenomena, the 
low-income countries have paid the price with their health including increased 
obesity and its associated co-morbidities [7] [8]. In low and middle-income 
countries, T2DM has shifted from being the 15th biggest cause of death in 1990 
to the 7th greatest in 2016 [8] [9] [10]. It has been reported that 80% of people 
diagnosed with T2DM are from low and middle-income countries [10]. 
The growing prevalence of obesity, and particularly childhood obesity, has led 
to a shift in T2DM to younger populations [3] [6] [11] [12] [13]. The estimate 
from the International Obesity Task Force indicates that about 155 million 
school-going children worldwide are obese [14]. It has also been observed that 
T2DM now accounts for about 45% of new onset diabetes in adolescents, as 
against 3% about 10 years ago [15]. 
New evidence is emerging indicating an association between hypovitaminosis 
D and insulin resistance amongst T2DM patients [12] [16]-[32]. Studies by re-
searchers including Lips et al. [33] found that in patients with established T2DM 
and in the general population, low levels of calcidiol (also known as calcifediol, 
25-hydroxycholecalciferol, or 25-hydroxyvitamin D [25(OH)D]) were associated 
with higher fasting glucose, insulin resistance and the metabolic syndrome [12]. 
25(OH)D exists in two major forms: ergocalciferol (vitamin D2) which is largely 
ingested, and cholecalciferol (vitamin D3) which is synthesized in the human 
body [16] [34]. Both forms are inactive, but are converted into an active form by 
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two enzymatic hydroxylation reactions: first, in the liver, forming 25-hydrox- 
yvitamin D mediated by 25-hydroxylase; and second in the kidneys mediated by 
1 α-hydroxylase, forming the final activated product calcitriol (1,25 dihydroxy-
vitamin D) [16] [34]. 25-hydroxyvitamin D is the circulating form of vitamin D 
in plasma, and an inverse relationship has been established between this and the 
prevalence of T2DM and impaired glucose tolerance [12] [35]. Several prospec-
tive studies showed that a low serum 25(OH)D baseline was associated with in-
cidence of T2DM [36]-[42]. A meta-analysis of prospective studies by Song et al. 
[43] also indicated an association between low circulating 25(OH)D levels and 
risk of T2DM.  
Several studies have explained the mechanisms through which vitamin D lev-
els are associated with T2DM [16] [33] [34] [44]. It has been proposed that vi-
tamin D influences T2DM in two ways: first, the active form 1,25 dihydroxyvi-
tamin D directly binds to β cell vitamin D receptors, thus facilitating insulin’s 
response to glucose [45] [46]; and second, through the regulation of calcium 
homeostasis through β cell membranes [34]. In this second case, vitamin D defi-
ciency (which alters the extracellular and intracellular β cell calcium pool) will 
adversely affect insulin secretion [39] [44].  
Vitamin D is present in some diets in micro-quantities, albeit rarely [45]. The 
major source of vitamin D (over 80%) is endogenous, but this requires ultravio-
let B radiation from sunlight to activate its precursor 7-dehydrocholesterol in the 
skin [45]. The evidence indicates that indoor lifestyles and protection from the 
sun’s rays have led to vitamin D deficiency even in countries with abundant 
sunlight [45]. 
In response to this vitamin D/T2DM theory, several studies have evaluated the 
effect of vitamin D supplementation on a variety of glycaemic outcomes, in-
cluding the effect of 25(OH)D on glycosylated haemoglobin (HbA1c) levels, 
plasma glucose levels and homeostatic model assessment insulin resistance 
(HOMA-IR). These reported conflicting results. For example, studies have found 
25(OH)D to be inversely related to HbA1c levels in diabetes mellitus [19] [28] 
[31]. Some studies reported a decrease in HbA1c and an increase in insulin sen-
sitivity on vitamin D supplementation [47]. Others, such as Ahmadi et al. [22], 
found no significant relationship between vitamin D and levels of HbA1c, while 
Elkassaby et al. [20] in a study on T2DM patients with vitamin D deficiency ob-
served a slight improvement in glycaemic outcomes measured by plasma glu-
cose.  
The few studies that measured the effects of vitamin D on HOMA-IR had 
varying outcomes. Some showed that vitamin D has a slight improvement effect 
on HOMA-IR [18] [32]; others showed that vitamin D supplementation in pa-
tients with T2DM did not significantly reduce insulin resistance [17].  
Owing to inconsistencies in these results and because these RCTs suffer the 
same shortcomings (low statistical power, lack of precision and small sample 
size), this study will systematically review the effects of vitamin D on glycaemic 
outcomes in T2DM patients. A systematic review is used because the pooled ef-
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fect of considering all RCTs increases the power of the research. 
2. Methods 
2.1 Search Strategy 
We performed a systematic review and meta-analysis in accordance with the 
standards set by the Preferred Reporting Items for Systematic Review and 
Meta-analysis (PRISM) checklist (Figure 1). We carried out an extensive elec-
tronic database search of published and unpublished RCTs, evaluating the asso-
ciation between vitamin D and glycaemic outcomes in T2DM patients. We 
searched Cochrane Library (Issue 6, 2014), PubMed, EMBASE, CINAHL Plus 
with Full Text, MEDLINE, BioMed Central, Turning Research Into Practice 
(TRIP), Health Technology Assessment (HTA), and Latin American and Carib-
bean Health Sciences (LILIACS) between the years 2005 and 2016. The full texts 
of relevant studies were retrieved, and references within them were followed up 
(“snowballing”) to discover studies missed in the initial search.  
We used keywords that followed the PICO guidelines (population, intervene- 
 
 
Figure 1. Flow diagram showing the study selection process. 
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tion, comparison and outcome): “type 2 diabetes patients” AND “vitamin D” OR 
“ergocalciferol” OR “cholecalciferol” AND “glucose metabolism” AND “glyco-
sylated hemoglobin” AND “randomized controlled trials”. The Boolean opera-
tors “AND” and “OR” were used to focus the search strategy. 
2.2. Study Selection 
Figure 1 illustrates how the PRISM checklist was used to document the process 
of study selection. The inclusion criteria were: a) participants were patients with 
T2DM irrespective of their age; b) the study design was RCT; c) the treatment 
group included patients who received vitamin D without calcium as an interven-
tion, compared with a control group who received placebo or non-vitamin D 
supplements; d) the studies measured changes in at least one of HbA1c, plasma 
glucose or HOMA-IR.  
The following studies were excluded: non-RCT studies; non-peer-reviewed 
studies; not enough detail given to judge the rigour of the methodology; studies 
that included patients with gestational diabetes; studies that included patients 
with pre-diabetes; studies where the full text cannot be assessed; and studies that 
compared supplementation of vitamin D with calcium. 
2.3. Data Extraction and Quality Assessment 
Data were extracted in duplicate by four independent reviewers (MAM, AB, EA 
and AO) [9]. Table 1 shows the data that were abstracted regarding the baseline 
characteristics of the included studies [9] – author, year of publication, study de-
sign, country of study, intervention and comparison, study size, participant age 
and loss to follow-up. Data were extracted and appraised with reference to 
methodological quality, outcome measures and predetermined criteria relevant 
to the research questions. 
Table 2 indicates data for glycosylated hemoglobin, blood glucose and 
HOMA-IR extracted from the included studies. Means and standard deviations 
are presented at a 95% confidence interval. It should be noted that some of the 
included studies reported blood glucose and HbA1c in different units; all units 
were converted to mg/dl for blood glucose (1 mmol/l = 18 mg/dl) and % for 
HbA1c. 
Figure 2 & Figure 3 illustrates how the internal and external validity, includ-
ing appraisal of random sequence generation, blinding treatment for subjects 
and personnel, outcome assessments, completeness of outcomes data, objective 
reporting and risks of potential bias, were evaluated using Review Manager 
(Revman) Version 5.3 [Computer program] the Nordic Cochrane Centre, the 
Cochrane Collaboration, 2014. 
2.4. Statistical Analysis 
The extracted data were analysed using revman. RevMan is statistical software 
used by the Cochrane Collaboration to prepare, analyse and interpret data for 
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systematic review and meta-analyses.  
Table 2 presents the data that were extracted analysed using revman 5.1. Het-
erogeneity was estimated statistically using Chi-squared tests (where P > 0.1 
suggested a lack of heterogeneity for continuous variables) and I-squared tests 
(where I2 > 75% was regarded as great heterogeneity). In addition, homogeneity 
was visually assessed using interpretation of forest plots. 
 
Table 1. Characteristics and quality assessment of included studies. 
Author Study  design 
Country of 
study Age of participants 
Study 
size/comparison Dose of vitamin D Loss to follow-up 
Vitamin D Placebo 
Ahmadi et al., 2013 RCT Iran (Isfahan) Older than 20 years 30 30 50,000 IU/week 9 
Al-Zahrani, 2014 RCT Saudi Arabia Not specified 100 100 
45,000 IU/week for two months, 
and a single dose of 45,000 IU in 
the last month 
17 
Breslavsky et al., 2013 RCT Not specified Mean age of 66.8 24 23 1000 IU/day for 12 months 15 
Elkassaby et al., 2014 RCT Australia 30 - 60 26 24 6000 IU/day Not specified 
Ghavamzadeh et al., 
2013 RCT Iran Mean age of 49.28 26 25 400 IU/day of vitamin D3 
Not 
specified 
Heshmat et al., 2012 RCT Iran (Tehran) 37 - 79 21 21 Single intramuscular injection of 300,000 IU of vitamin D3 
Not 
specified 
Jehle et al., 2014 RCT Switzerland >16 29 26 300,000 IU of vitamin D3 Not specified 
Jorde et al.,2009 RCT North Norway 21 - 76 16 16 40,000 IU/week cholecalciferol 4 
Kampmann, 2014 RCT Denmark >18 7 8 
11,200 IU/day cholecalciferol for 
two weeks and 5600 IU/day for 
10 weeks 
1 
Kota et al., 2012 RCT India  (Hyderabad) 22 - 63 15 15 Not specified 
Not 
specified 
Neyestani et al., 2012 RCT  30 - 60 30 30 500 IU/day vitamin D and 150 mg calcium/250ml/day 
Not 
specified 
Ryu et al., 2013 RCT South Korea Not specified 79 79 
1000 IU cholecalciferol daily 
combined with 100mg of 
elemental calcium twice daily 
29 
Shar-Bidar et al., 2011 RCT Iran (Tehran) 29 - 67 50 50 
Vitamin D fortified yoghurt (170 
mg calcium and 150 IU vitamin 
D) 
Not 
specified 
Strobel et al., 2014 RCT Germany 30 - 78 39 33 20 drops of Vigantol oil/ week (1904 IU/day) 14 
Sugden et al., 2007 RCT Scotland Mean age of 64.2 17 17 A single dose of 100,000 IU vitamin D2 9 
Thethi et al., 2015 RCT USA 18 - 70 30 30 1 mcg paricalcitol 5 
Yousefi Rad et al., 2015 RCT Iran 30 - 60 28 30 4000 IU/day 7 
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Table 2. Data extraction. 
Author Outcomes 
Intervention Control 
Number of participants (N1) Mean SD Number of participants (N2) Mean SD 
Ahmadi et al., 2013 HbA1c (%) 28 7.22 1.2 23 7.09 1.4 
Al-Zahrani, 2014 
HbA1c (%) 
91 
8.6 1.6 
92 
8.7 1.8 
FBG (mmol/l) 9.3 3.1 10 3.7 
Breslavsky et al., 2013 
HbA1c (%) 
19 
7.3 1.1 
13 
7.2 1.7 
FBG (mmol/l) 8.66 3.06 8.36 3.53 
Elkassaby et al., 2014 
HbA1c (%) 
26 
6.15 0.25 
24 
6.1 0.2 
FBG (mmol/l) 6.85 0.25 6.43 0.33 
Ghavamzadeh et al., 2013 HbA1c (%) 26 6.6 2.35 25 8.42 3.35 
Heshmat et al., 2012 
HbA1c (%) 
21 
6.49 0.9 
21 
6.5 0.9 
FBG 8.32 1.62 7.18 1.67 
Jehle et al., 2014 
HbA1c 
29 
7.2 1.1 26 7.7 0.9 
HOMA-IR 3.9 2.2  4.4 2.5 
Jorde et al., 2009 
HbA1c (%) 
16 
7.8 0.9 
16 
7.7 0.5 
FBG (mmol/l) 9.6 3.1 9.6 1 
HOMA-IR 27.9 23.5 24.8 13.7 
Kampmann, 2014 
HbA1c (%) 
7 
0.0678 0.005 
8 
0.083 0.006 
FBG (mmol/l) 7.17 1.06 10.03 1.7 
Kota et al., 2012 
HbA1c (%) 
15 
7.7 0.9 
15 
7.8 1.1 
FBG (mmol/l) 7.96 1.24 8.14 1.19 
Neyestani et al., 2012 HOMA-IR 30 2.7 1.5 30 5.5 3.7 
Ryu et al., 2013 HbA1c (%) 64 7.4 0.9 65 7.27 0.87 
Shar-Bidar et al., 2011 HbA1c (%) 50 7.8 1.3 50 8.5 1.6 
Strobel et al., 2014 
HbA1c (%) 
39 
6.1 0.76 
33 
6.68 1 
FBG (mmol/l) 7 1.31 6.82 1.7 
Sugden et al., 2007 HbA1c (%) 17 7.51 0.6 17 6.25 0.39 
Thethi et al., 2015 HbA1c (%) 23 7.85 1.3 23 7.73 1.13 
Yousefi Rad et al., 2015 HbA1c (%) 28 6.76 0.95 30 7.73 1.26 
3. Results 
This research hypothesized that vitamin D will effectively improve glucose me-
tabolism in type 2 Diabetes mellitus patients. Figure 4 is the forest plot of 15 tri-
als that compared the effect of vitamin D on HbA1c. An increase in glycosylated 
hemoglobin (HbA1c) means that glucose metabolism was not improved with vi-
tamin D supplementation. Conversely, a decrease in HbA1c depicts an im-
provement in glucose metabolism with vitamin D supplementation. The average 
HbA1c was slightly lower in the 25(OH)D than control, but the difference was  
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Figure 2. Assessment of risk of bias of individual studies. 
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Figure 3. Graphic summary of assessment risk of bias for included studies. 
 
 
Figure 4. Forest plot of 15 trials that compared effect of vitamin D and placebo on the levels of glycosylated haemoglobin 
(HbA1c). 
 
not statistically significant (P = 0.56; MD = −0.06; 95% CI = −0.26 to 0.14); the 
95% confidence interval crosses the line of no effect.  
Figure 5 is a forest plot of seven studies that compared the effect of vitamin D 
and placebo on blood glucose. An increase in blood glucose indicates that vita-
min D supplementation did not improve glucose metabolism, while a decrease 
indicates an improvement. The figure shows a pooled estimated mean of −0.03 
indicating an average decrease in plasma glucose in the 25(OH)D group com-
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pared to control. However, the difference was not statistically significant (P = 
0.95; 95% CI: −0.69 to 0.63); the 95% confidence interval crosses the line of no 
effect. 
Figure 6 is a forest plot of studies that compared the effect of vitamin D and 
placebo on homeostatic model assessment insulin resistance (HOMA-IR). The 
data show a pooled estimate of MD = −1.51, indicating an improvement in av-
erage HOMA-IR in the 25(OH)D group compared to control. However, the dif-
ference was not statistically significant (P = 0.16; 95% CI = −3.61 to 0.60), and 
the 95% confidence interval crosses the line of no effect. 
Figure 7 and Figure 8 show a single study that compared the effect of vitamin 
D and non-pharmaceutical intervention (counselling) on glycosylated haemo-
globin and blood glucose respectively. Nothing was administered to the control 
group in this study; however, participants were counselled on how to naturally 
increase vitamin D levels. The authors thought to separate this study from the 
studies that compared vitamin D with placebo, since the study has a different 
comparator which may affect the heterogeneity of the study results. 
 
 
Figure 5. Forest plot of 7 trials that compared effect of vitamin D and placebo on blood glucose. 
 
 
Figure 6. Forest plot of 3 trials that compared effect of vitamin D and placebo on homeostatic model assessment insulin resistance 
(HOMA-IR). 
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Figure 7. Study that compared effect of vitamin D and non-pharmaceutical intervention on glycosylated hemoglobin. 
 
 
Figure 8. Study that compared effect of vitamin D and non-pharmaceutical intervention on blood glucose. 
4. Discussion 
Our systematic review identified 929 studies and 148 RCTs that evaluated the 
effect of vitamin D supplementation on three glycaemic outcomes – plasma glu-
cose, HbA1c and HOMA-IR. A total of 15 studies compared vitamin D with 
placebo and measured glycosylated haemoglobin (HbA1c) as the endpoint out-
come with a total of 791 participants, 402 in the vitamin D group and 389 in the 
placebo group. In relation to vitamin D and HbA1c, the results showed a slight 
reduction in HbA1c in the vitamin D group compared to the placebo group 
(mean difference = −0.06; 95% CI = −0.26 to 0.14; I2 = 84%). However, the re-
duction was not statistically significant (P = 0.56). These findings are typical of 
most intervention studies evaluating the effect of vitamin D on T2DM, which 
give signals of nominal significance for diverse outcomes that are inconclusive 
and subject to caveats [48] [49]. It is also consistent with previous systematic re-
views, including one by Seida et al. which included 15 RCTs and examined the 
effects of vitamin D on HbA1c in individuals with normal glucose tolerance and 
individuals with T2DM [49]. 
The conclusive evidence of association between increases in 25(OH)D and 
decreases in HbA1c levels come from observational studies [50] [51] [52] [53]. 
For example, a longitudinal study by Munasinghe et al. [50] found that the mean 
serum 25(OH)D concentrations of participants on vitamin D supplementation 
increased from 90.8 nmol/L at baseline to 121.3 nmol/L at follow-up, while the 
mean HbA1c values decreased from 5.6% at baseline to 5.5% at follow-up. The 
prevalence of participants with increased diabetes risk, i.e. those with HbA1c 
values ≥ 5.8%, decreased from 29.5% to 17.4% [50]. This signifies the need for 
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further investment into research in this area. 
For effects of vitamin D on plasma glucose, a total of seven studies [17] [20] 
[21] [24] [25] [29] were examined; these had a total of 273 participants, 143 in 
the vitamin D group and 130 in the control group. The study showed a MD = 
−0.03 mmol/l and a 95% CI = −0.69 to 0.63 in favour of the 25(OH)D group. 
Consistent with previous intervention studies which showed nominal improvements 
in plasma glucose, these findings were statistically insignificant (P = 0.93; 95% 
CI = −0.69 to 0.63). Similarly, Seida et al.’s [49] systematic review of 25 RCTs 
showed minimal effects (MD = −0.18 mg/dL; 95% CI = −1.26 to 0.90; I2 = 21%) 
of vitamin D on blood glucose in individuals with normal glucose tolerance, 
pre-diabetes and patients with T2DM. Similar results were shown in another 
systematic review by George, Pearson and Witham, [54]. More conclusive evi-
dence of the link between vitamin D and FPG came from an observational study 
by Pannu et al. [52] which showed that every 10 nmol/L increment in serum 
25(OH)D significantly reduced the adjusted odds ratio (AOR) of a higher FPG 
(AOR = 0.91, (0.86, 0.97); P = 0.002] and a higher HbA1c (AOR 0.94, (0.90, 
0.98); P = 0.009). 
Homeostatic Model Assessment Insulin Resistance (HOMA-IR) is the most 
common measure of insulin sensitivity. We found three studies which met our 
inclusion criteria [17] [18] [32] and measured effects of vitamin D on 
HOMA-IR. Together these had 147 participants, 67 in the vitamin D group and 
65 in the control group. The result showed that vitamin D has a slight improve-
ment effect on HOMA-IR (MD = −1.51; 95% CI = −3.61 to 0.60; I2 = 67%); 
however, a P value = 0.16 shows that the effect of vitamin D was not significant. 
This study showed that vitamin D supplementation in patients with T2DM did 
not significantly reduce insulin resistance. Comparably, Seida et al. [49] included 
six studies that examined the effects of vitamin D supplementation on 
HOMA-IR in T2DM patients [55]. They also found no significant difference in 
the vitamin D group compared to the placebo group (MD = −1.46; 95% CI = 
−4.27 to 1.34). 
Overall, a lack of consensus on the effect of vitamin D supplementation con-
tinues to exist among the intervention studies. The consistent feature amongst 
all of them is lack of statistical significance. Even systematic reviews that com-
bine several RCTs failed to increase statistical power and estimates of precision 
[49] [56]. This calls for further research into this issue using larger sample sizes. 
5. Conclusion 
In conclusion, although vitamin D has been extensively studied in relation to 
glycaemic outcomes and indications that increased plasma vitamin D concentrations 
might be linked to prevention of T2DM, firm universal conclusions about its 
benefits cannot be drawn. Further studies with better designed trials and larger 
sample sizes are needed to draw firmer conclusions.  
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6. Limitations of the Study 
It is important to note that the major strength of this review is its strict adher-
ence to the methods and guidelines included in the Cochrane handbook of sys-
tematic reviews. It also included the most recent RCTs which provide up-to-date 
evidence. However, it was not without its limitations: the funding for this study 
only covered the lead researcher’s time and did not cover resources; conse-
quently, several studies that looked promising from the reviews of their abstracts 
were excluded due to limited funds to purchase the full text. 
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